Medical Science Liaison Research Articles

Biotechnology's special forces: Field-based medical science liaisons

Biotechnology companies with a product commercialisation strategy are deploying field-based medical science liaisons (MSLs) to increase awareness of a therapeutic market, support clinical trials, and educate the healthcare community on appropriate product utilisation. Attracting experienced MSLs to smaller or younger companies remains a significant challenge for MSL directors. Comprehensive MSL training programmes are also lacking at young biotechnology companies, even though directors interviewed in this paper all agreed that training is a key provision to equip MSLs for quality performance. As field-based medical programmes are expanding in the biopharmaceutical industry, small MSL teams often compete in the same market dominated by large pharmaceutical MSL forces. Small teams that are staffed with experienced MSLs, trained rigorously on both technical and non-technical competencies, and motivated toward effective teamwork are positioned for success. Medical science liaison directors who proactively communicate with senior management on the value that MSLs bring to their companies are more likely to obtain resources for training and will leverage their MSL programmes for growth.

Biotechnology's special forces: Field-based medical science liaisons

Biotechnology companies with a product commercialisation strategy are deploying field-based medical science liaisons (MSLs) to increase awareness of a therapeutic market, support clinical trials, and educate the healthcare community on appropriate product utilisation. Attracting experienced MSLs to smaller or younger companies remains a significant challenge for MSL directors. Comprehensive MSL training programmes are also lacking at young biotechnology companies, even though directors interviewed in this paper all agreed that training is a key provision to equip MSLs for quality performance. As field-based medical programmes are expanding in the biopharmaceutical industry, small MSL teams often compete in the same market dominated by large pharmaceutical MSL forces. Small teams that are staffed with experienced MSLs, trained rigorously on both technical and non-technical competencies, and motivated toward effective teamwork are positioned for success. Medical science liaison directors who proactively communicate with senior management on the value that MSLs bring to their companies are more likely to obtain resources for training and will leverage their MSL programmes for growth.

Journey to the pharmaceutical industry and back: my experience as a medical science liaison.

Journey to the pharmaceutical industry and back: my experience as a medical science liaison.

Function of the human liver in IgA homeostasis in plasma.

Annals of the New York Academy of SciencesVolume 409, Issue 1 p. 383-401 FUNCTION OF THE HUMAN LIVER IN IgA HOMEOSTASIS IN PLASMA* D. L. Delacroix, D. L. Delacroix Gastroenterology Laboratory University Clinic of St. Luke International Institute of Cellular and Molecular Pathology Experimental Medicine Unit Catholic University of Louvain Brussels, BelgiumSearch for more papers by this authorJ. P. Vaerman, Corresponding Author J. P. Vaerman Gastroenterology Laboratory University Clinic of St. Luke International Institute of Cellular and Molecular Pathology Experimental Medicine Unit Catholic University of Louvain Brussels, Belgium†Correspondence to: J. P. Vaerman, UCL—ICP—MEXP, 75, avenue Hippocrate, B—1200 Brussels, Belgium.Search for more papers by this author D. L. Delacroix, D. L. Delacroix Gastroenterology Laboratory University Clinic of St. Luke International Institute of Cellular and Molecular Pathology Experimental Medicine Unit Catholic University of Louvain Brussels, BelgiumSearch for more papers by this authorJ. P. Vaerman, Corresponding Author J. P. Vaerman Gastroenterology Laboratory University Clinic of St. Luke International Institute of Cellular and Molecular Pathology Experimental Medicine Unit Catholic University of Louvain Brussels, Belgium†Correspondence to: J. P. Vaerman, UCL—ICP—MEXP, 75, avenue Hippocrate, B—1200 Brussels, Belgium.Search for more papers by this author First published: June 1983 https://doi.org/10.1111/j.1749-6632.1983.tb26884.xCitations: 46 * This study was supported by grants No. 4.4504.70 and No. 220992 from the Medical Science Research Foundation, Brussels. D. L. Delacroix is Senior Research Assistant at the National Scientific Research Foundation, Brussels. Financial support was also given by the Medical Science Liaison, Puurs, Belgium. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume409, Issue1The Secretory Immune SystemJune 1983Pages 383-401 RelatedInformation

Measuring performance of field-medical programmes: Medical science liaison metrics consensus

A Medical Science Liaison (MSL) Metrics Consensus initiative aims to identify field-medical activities throughout the pharmaceutical product lifecycle, and metrics associated with those activities. Since MSL programme deployment strategies may vary from company to company, pharmaceutical executives often use retrospective benchmarking studies to assist their field-medical teams in establishing programme metrics. This Medical Science Liaison Metrics Consensus initiative is the first of its kind to identify activities that are unique to field-based MSL team capabilities. Upon identification of unique contribution of MSL teams across the product lifecycle, metrics were identified and associated with MSL activities across the product lifecycle, with an emphasis on outcomes and compliance. Organisations may use the results of this Medical Science Liaison Metrics Consensus to proactively assess and design their MSL programmes' current valuation standards.